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Abstract: 3β-Hydroxysteroid dehydrogenase type II defi-
ciency (3βHSD2) congenital adrenal hyperplasia is a rare 
cause of ambiguous genitalia, resulting in abnormal virili-
sation in both 46XY and 46XX. We describe a case of 46XY 
ambiguous genitalia that was misdiagnosed as androgen 
insensitivity syndrome. The correct diagnosis was made 
after adrenarche. Genotyping demonstrated compound 
heterozygosity in two alleles, the previously described 
c.244G>A (p.Ala82Thr), and a novel 931C>T(p.Gln311*) 
variant. We suggest that adrenarche unmasked the condi-
tion by driving cortisol production to rates that caused the 
mutant 3βHSD2 enzyme to become rate limiting for cortisol 
production. This case illustrates how markedly different 
the effects of this condition may be on androgen produc-
tion compared with glucocorticoid and mineralocorticoid 
production. It also demonstrates how current guidelines 
based on urinary steroids and cortisol sufficiency may not 
arrive at the correct diagnosis, and underlines the impor-
tance of gene testing in the work-up of disorders of sexual 
differentiation.
Keywords: adrenarche; c.244G>A (p.Ala82Thr); congeni-
tal adrenal hyperplasia; 931C>T (p.Gln311*); disorders of 
sexual differentiation; 3β-hydroxysteroid dehydrogenase 
deficiency; virilisation.
Introduction
Adrenarche is still described as one of the least 
 understood of human endocrine developmental events. 
Whilst adreno-cortico-tropic hormone (ACTH) has been 
considered an essential hormone for the development of 
adrenarche, the observation that ACTH and cortisol levels 
remain constant throughout adrenarche despite the rise in 
adrenal androgens have caused some to argue that there 
must be another stimulator for adrenarche [1].
We describe a case of biochemical unmasking of 3β- 
hydroxysteroid dehydrogenase type II deficiency (3βHSD2) 
after infancy. The hypothesis generated through this case 
focuses on enzyme activities in the zona fasciculata. 
Whilst ACTH and cortisol levels in serum remain constant 
throughout adrenarche, there is an increased metabolism 
and excretion of cortisol [2]. Central to our hypothesis is 
that this increased metabolism and excretion of corti-
sol during adrenarche must be balanced by an increased 
production of cortisol. Rainey’s group [3, 4] reported 
increasing immuno-intensity of CYP17 after age five and 
plateauing at age 13 in not just zona reticularis but also in 
zona fasciculata (ZF). Given that CYP17  has only 17α 
hydroxylase activity in the ZF [5], this finding is consist-
ent with an increased production of cortisol through 
adrenarche in normals. Adrenarche might then tip the 
balance in a patient with limited reserve for cortisol pro-
duction, such as is in the case in our patient with 3βHSD2 
deficiency. A state of cortisol insufficiency may thus ensue 
resulting in secondary elevation in ACTH, and the steroid 
picture characteristic of 3βHSD2 deficiency.
Case presentation
The patient born at term following an uncomplicated 
pregnancy in Brisbane was noted to have ambiguous 
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genitalia with testes in the scrotum, a vaginal introitus, 
perineal urethra and a small phallus. The karyotype 
was 46XY. The diagnosis was presumed to be androgen 
insensitivity, although human chorionic gonadotropin 
(hCG) stimulation test commenced at 4  days of age was 
not consistent with this (Table 1). Urine steroid profile 
by gas chromatography mass spectrometry at 5  days of 
age was not suggestive of congenital adrenal hyperplasia 
(CAH) due to 21-, 11-hydroxylase or 3β-hydroxy-steroid-
dehydrogenase type II (3βHSD2) deficiency (Table 2). 
Assays for 17α-hydroxyprogesterone (17αOHP) and/or 
17-hydroxypregnenolone (17OHpreg) do not appear to 
have been performed. She underwent laparoscopy at 
13 days of age, revealing absent uterus and ovaries, and at 
the same time underwent gonadectomy. Histopathology of 
the testes were of 12 × 8 × 7 mm left testis and 14 × 7 × 5 mm 
right testis with unremarkable histology consistent with 
age and with no evidence of malignancy. Vas deferens and 
epididymal tissue were histologically normal.
DNA testing on the patient at 5 years of age and on the 
mother showed no mutations or deletions of the andro-
gen receptor gene, though less than 50% of probands with 
partial androgen insensitivity syndrome will have patho-
genic variants detected on sequencing of the AR gene.
Examination findings at 6  years of age noted labial 
folds, a 4  cm phallus and perineal urethra opening just 
above the vagina. Growth consistently followed the 50th 
percentile for weight and the 75th percentile for height. 
The patient identified as a female.
At 9  years of age the patient developed premature 
pubic hair, but no axillary hair. There were a few pimples 
but no acne. This evidence of early adrenarche was not in 
keeping with the diagnosis of androgen insensitivity syn-
drome. She was troubled by genital irritation secondary 
to 4 cm clitoromegaly and erections from 11 years of age. 
ACTH levels were up to 6 times the upper limit of normal, 
and hydrocortisone 8 mg mane was trialled to see whether 
suppression of ACTH stimulation of adrenal androgens 
might help minimise the clitoromegaly. ACTH did drop 
to three times the upper limit of normal, but the patient 
decided to cease hydrocortisone and undergo elective clit-
oral reduction at 14 years of age. Hyperpigmentation did 
not occur.
Hyperkalaemia in a haemolysed sample at 10.5 years 
of age prompted assessment of adrenal function. Urine 
steroid profile demonstrated elevated de-hydro-epi-
androstenedione (DHEA), pregnanetriol and pregnentriol 
and low excretion of cortisol metabolites; cortisone and 
cortisol (Table 2). Given the XY genotype, these results 
were reported to be consistent with 3βHSD2 deficiency, 
although there was no quantification of pregnanetriol and 
no report of pregnentriolone for determination of their 
ratio, which is considered to be the best means of discrimi-
nating this disorder from 21-hydroxylase CAH. Consistent 
with the diagnosis, basal 17OHPreg was elevated, adrenal 
androgens were elevated, testosterone was normal and fol-
licle stimulating hormone (FSH) was elevated (Table 3). 
Interestingly there was relatively less effect on mineralo-
corticoids and glucocorticoids compared with sex steroids.
Table 1: Neonatal hCG stimulation test.
4–5 days 9–10 days
hCG Test 
 Free testosterone 4.8 pmol/L (day 0) 3.9 pmol/L (day 5)
(< 2.0 pmol/L) (2–4 × baseline)
 DHT 1.54 nmol/L (day 1) 1.4 nmol/L (day 5)
– (T : DHT < 10 : 1)
 LH 8 U/L (day 1) 2 U/L (day 5)
 FSH < 2 U/L (day 1) < 2 U/L (day 5)
 Androstenedione Not performed Not performed
Table 2: Urinary steroid analysis.
  5 days old   10.5 years of age
Androsterone   < 0.1 μmol/24 h (< 1.5)  1.9 μmol/24 h (< 1.5)
Etiocholanolone   < 0.1 μmol/24 h (< 1.2)  1.5 μmol/24 h (< 1.2)
Pregnanetriol   < 0.1 μmol/24 h (< 0.8)  9.2 μmol/24 h (< 0.8)
Pregnanediol   –   1.2 μ/24 h (< 0.3)
Pregnenetriol   –   –
Preg. Triolone   < 0.1 μmol/24 h (< 0.5)  –
TH-Deoxycortisol   < 0.1 μmol/24 h (< 0.5)  0.2 μmol/24 h (< 0.5)
TH-Cortisone   < 0.1 μmol/24 h (< 4.5)  1.9 μmol/24 h 
(3.0–10.0)
TH-Cortisol   < 0.1 μmol/24 h 
(0.1–1.0)
  0.6 μmol/24 h 
(0.6–3.0)
Table 3: Serum analysis.
  10.5 years of age
17 Hydroxy-pregnenolone  376.7 nmol/L (0.0–10.0)
  Diagnostic if > = 29 nmol/L (13) 
or 69 nmol (14)
DHEA-S   9.1 μmol/L (0.3–1.6)
Androstenedione   4.5 nmol/L (1.0–1.8)
Testosterone   2.2 nmol/L (0.3–2.8 females)
FSH   100 U/L ( < 12)
Plasma renin activity   55 mU/L upright ( < 40) 
Aldosterone   597 pmol/L (100–850) 
Na   Normal
K   Normal
ACTH   147 ng/L (9–51) 
Cortisol   524 nmol/L
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Oestrogen hormone replacement therapy was com-
menced at 12.25 years of age, later than is typically done, 
and was up titrated relatively slowly. The patient ulti-
mately reached 180.2 cm in height, significantly taller than 
the 171.5 cm predicted from mid-parental height. Her bone 
age at 16 years of age was 14 years, in keeping with low 
oestradiol levels resulting in delayed epiphyseal closure.
The patient had minor breast development, but at 
20 years of age sought breast augmentation. Bone mineral 
densitometry has been ordered to assess for any adverse 
effects from low oestradiol levels.
Next generation and Sanger sequencing at 21 years of 
age confirmed two variants in the HSD3B2 gene, c.244G>A 
(p.Ala82Thr) which has been previously described in 
patients with non-salt wasting classical 3βHSD2 defi-
ciency [6], and the novel 931C>T (p.Gln311*) variant in 
exon 4, which interrupts the reading frame and introduces 
a premature STOP codon at amino-acid position 311, likely 
resulting in a truncated protein product or degradation 
of the transcript via nonsense mediated decay. The latter 
variant has not been previously described in the litera-
ture, Human Gene Mutation Database or patients tested 
by our laboratory. Parental studies were not performed, 
but given the phenotype we feel we can assume these two 
variants are on separate alleles.
The patient has never required supplementation with 
glucocorticoids, and there were no significant symptoms 
or signs suggestive of mineralocorticoid insufficiency 
(although as-required fludrocortisone was initiated in 
light of some thirst and dizziness in hot weather).
The family felt the gonadectomy as an infant was 
rushed, with confusion over that decision throughout her 
childhood. Psychologist consultation at 14  years of age 
prior to clitoral reduction surgery opined the patient had 
a clear, unambivalent view that she is female, but with 
both male and female traits with which she was comfort-
able. This lack of ambivalence and confusion was felt to 
be a concern possibly relating to some level of denial or 
anxiety. Nonetheless she is now a well 21-year-old woman 
and is highly functioning, performing well at university 
and in her occupation. She is aware that gonadectomy as 
an infant means she cannot conceive children, and is not 
discontent in this knowledge. She has a sexual interest in 
males and is successfully pursuing vaginal dilatation.
Discussion
This is a case of 46XY disorder of sexual development 
that was misdiagnosed. It raised a number of discussion 
points.
Epidemiology
3βHSD2 deficiency accounts for less than 5% of CAH 
worldwide [7]. Its prevalence is too low to be accurately 
estimated, although rates are much higher in popula-
tions with high rates of consanguinity. The cause of 46XY 
ambiguous genitalia varies in different populations, and 
in many cases a secure diagnosis is not made. It has been 
suggested that epigenetic variations or environmental 
factors play a role [8].
Inconsistency between the severe effects 
on androgen production and the  relatively 
mild effects on glucocorticoid and 
 mineralocorticoid production
There have been more than 40 mutations reported in the 
HSD3B2 gene affecting enzyme activity to varying degrees 
[9]. The in vitro enzyme activity of the mutant enzyme is 
mostly in keeping with the degree of salt wasting [9, 10]. 
Our patient exhibited evidence of inadequate in-utero 
exposure to testosterone and dihydro-testosterone, but 
exhibited only minor effects on mineralocorticoids and 
glucocorticoids, potentially obscuring the diagnosis of 
3βHSD2 deficiency in CAH. As was the case with our 
patient, the degree of salt wasting does not correlate with 
the impairment in male sexual differentiation, which 
can range from hypospadias to ambiguous genitalia [10]. 
Neither does the degree of salt wasting correspond to 
serum testosterone levels, with both low and high neo-
natal serum testosterone levels reported in cases of salt 
wasting and simple virilising forms [9, 11–14].
There are multiple pathways for androgen biosynthe-
sis in the gonads that are essential for normal male sexual 
differentiation [15]. There are also multiple pathways for 
peripheral conversion of androgens to active forms [16]. 
It may be that inter-individual variability in these path-
ways and the androgen targets may explain the variable 
disorders of sexual differentiation (DSD) phenotype on 
patients with 3βHSD2 deficiency and other forms of CAH.
The misdiagnosis
There was a failure to make the correct diagnosis as a 
neonate in our patient.
According to the UK guidelines for diagnosis of disorders 
of sexual differentiation patients with 3βHSD2 deficiency 
typically demonstrate low testosterone, low testosterone 
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response to hCG with elevated DHEA, DHEAS and andros-
tenedione, an abnormal short synacthen test and abnormal 
urinary steroid profile [17]. Whilst there are hormonal crite-
ria proposed for the diagnosis of 3βHSD2 deficiency, based 
on ACTH-stimulated 17OHPreg and 17OHPreg : cortisol 
ratios [18, 19], urinary steroids tend to be used instead.
hCG stimulation testing is often done for diagnostic 
management of 46XY DSD despite having poor utility in 
distinguishing patients with disorders of androgen syn-
thesis from disorders of androgen action [8]. A diagnosis 
of partial androgen insensitivity was presumably based 
on an abnormally elevated basal free testosterone despite 
an abnormal response to hCG stimulation testing, which 
may have reflected a lack of confidence in the test and 
high pre-test probability of androgen insufficiency as the 
diagnosis. A free testosterone immunoassay is unreliable, 
particularly at the low concentrations seen in the neona-
tal population. We suggest that the basal free testosterone 
in our patient was falsely elevated due to laboratory error, 
and hCG stimulation test was either misinterpreted or felt 
it to be unreliable.
The presence of peripheral 3βHSD type I activity often 
complicates the diagnosis of this disorder as very high 
levels of 5-ene steroids (DHEA, 17-hydroxypregnenolone 
and pregnenolone) may be converted extra-adrenally to 
4-ene steroids (androstenedione, 17OHP and progesterone) 
thus suggesting the diagnosis of 21-hydroxylase deficiency. 
Urinary steroids have been shown to discriminate 3βHSD2 
deficiency from 21-hydroxylase deficiency and normals in 
the neonate, based on high ratios of pregnenetriol : corti-
sol metabolites or pregnenetriol : pregnetriolone [20]. The 
urinary steroid profile in our case as a neonate did not 
demonstrate any excess metabolites of adrenal steroids, 
which is inconsistent with the urinary steroid profile per-
formed at 10.5 years of age, where there were clear abnor-
malities. The adrenal produces approximately two thirds 
of fetal cortisol towards the end of a pregnancy, with the 
remainder being derived maternally. Urinary steroids drop 
in normal neonates within the first week of life [21], after 
maternal-derived steroids have been excreted. If there was 
an inability of the neonatal adrenal gland to produce ade-
quate cortisol then a compensatory rise in ACTH should be 
anticipated within the first week of life. The normal day 5 
urinary steroid pattern in our patient suggests that she was 
producing adequate cortisol as a neonate.
How then can the inconsistency in urinary steroid 
pattern at the two time points be explained? The patient’s 
mother was not exposed to β-methasone prior to delivery 
[22]. One hypothesis is the inconsistency in urinary steroid 
pattern is related to the changes in adrenal steroidogenic 
enzyme expression at adrenarche. The zona reticularis 
in the adult adrenal gland has very low expression of 
3βHSD2 and high greater expression of enzymes higher 
in the steroidogenesis pathway. The zona reticularis 
expands and the expression of 3βHSD2 in the zona reticu-
laris has been demonstrated to decline through a normal 
childhood into adrenarche [9]. This may explain the 
increased concentrations of DHEAS seen at adrenarche. 
It might be anticipated that with reduced enzyme activ-
ity associated with a mutated HSD3B2 gene, an exagger-
ated or early adrenarche occurs. This would account for 
the premature development of pubic hair in our patient. 
Another adrenal enzyme that markedly alters expression 
during adrenarche is CYP17. It increases in expression in 
not just the zona reticularis but also the zona fasciculata 
where it has only 17α hydroxylase activity, in keeping 
with an increase in cortisol production [5, 18, 23]. Corti-
sol metabolism is known to increase through puberty 
due to increased activity of 11-β-hydroxysteroid dehydro-
genase type I and increased glomerular filtration rate [2]. 
It may then be hypothesised that the enzyme product of 
a mutated HSD3B2 gene in the zona fasciculata becomes 
rate limiting for cortisol production when the cortisol pro-
duction rate increases at adrenarche.
Should this hypothesis be correct, then even with an 
improved testosterone assay, the recent UK guidelines 
for determining aetiology of disorders of sexual devel-
opment would still misdiagnose this condition. At birth 
there would have been an adequate cortisol response 
to synacthen, resulting in an incorrect diagnosis of 
17-β-hydroxysteroid dehydrogenase type III (17βHSD3) 
deficiency CAH. Incidentally 17βHSD3 looks phenotypi-
cally very similar to 3βHSD2, both virilising at adrenarche. 
The mechanism for virilisation of 46XY patients with 
17βHSD3 deficiency at adrenarche is unknown, but has 
been hypothesised that elevated androstenedione is con-
verted to more active androgens by increased expression 
of 17βHSD type V in muscle at adrenarche [24]. It may be 
that the same mechanism is responsible for adrenarchal 
virilisation in 3βHSD2 deficiency.
The role and timing of surgery
46XY with 3βHSD2 deficiency raised as males are unlikely 
to be fertile but have a low risk of malignancy [13]. Accord-
ing to the 2006 consensus statement, children with 46XY 
DSD should be raised as male if there is evidence of andro-
gen responsiveness, including phallic development, or as 
female if potential for androgen responsiveness is lacking 
[25], but the decision regarding gender assignment should 
also consider specific diagnosis, genital anatomy, surgical 
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options, potential for fertility, potential for adult sexual 
responsiveness function and factors that may predict most 
likely adult gender identity.
A recent publication has added 3βHSD2 deficiency to 
the short list of conditions associated with spontaneous 
virilisation at puberty of patients with 46XY karyotype 
[13]. Remarkably, there have even been reports of spermat-
ogenesis in males with moderate to severe DSD resulting 
from 3βHSD2 deficiency. This adds weight to the argument 
that testes should be retained until a definite gender pref-
erence becomes clear.
Conclusions
There was a failure to make the correct diagnosis as a 
neonate in our patient for a number of reasons: false ele-
vation of the basal free testosterone, misinterpretation or 
lack of confidence in the accuracy of the hCG stimulation 
test (demonstrating no testosterone increment), and neg-
ative urinary steroid profile which was inconsistent with 
the published criteria for diagnosis of CAH. We suggest 
that this is a result of adrenarche unmasking the condi-
tion by driving cortisol production to rates that cause the 
mutant 3βHSD2 enzyme to become rate limiting for cor-
tisol production. The sequelae from the misdiagnosis in 
this case include a potential for virilisation and fertility 
that was not recognised, gender assignment forced by 
gonadectomy, and significant distress to the family.
We suggest that a gene panel be performed in all cases 
of disorders of sexual development.
Take home messages
1. 3βHSD2 deficiency can present with ambiguous geni-
talia in both 46XY and 46XX karyotypes.
2. Glucocorticoid, mineralocorticoid and sex steroid pro-
duction can be affected to differing degrees depend-
ing on the mutation in the HSD3B2 gene.
3. Androgen production may not be in keeping with glu-
cocorticoid or mineralocorticoid production.
4. There should be appropriate work-up of cases of 
ambiguous genitalia to optimise the chance of a cor-
rect diagnosis and best long-term outcome.
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